Abstract
Bone-marrow-derived mesenchymal stromal cells (BMSCs) showed therapeutic potential in the treatment of musculoskeletal diseases, including osteoarthritis (OA). Their soluble mediators and extracellular vesicles (EVs), which make up the secretome, suppress immune response, attenuate inflammation and promote cartilage repair. EVs, as well as the whole secretome, have been investigated as cell free approaches for OA although, to date, a disease-tailored molecular fingerprint is missing. In this study, soluble mediators and miRNAs were sifted in the BMSCs’ secretome and EVs, respectively, and analyzed in the frame of cell types and factors involved in OA. The majority of identified molecules repress the activation of immune cells and the production of OA-related inflammatory mediators, as well as promote cartilage protection by acting on both chondrocytes homeostasis and extracellular matrix-degrading enzymes. These data provide the molecular ground for the therapeutic potential of BMSCs for regenerative applications for OA and support the use of secretome or EVs as cell-free applications in joint diseases.
Reference80 articles.
1. Osteoarthritis;Lancet,2019
2. Ageing and the pathogenesis of osteoarthritis;Nat. Rev. Rheumatol.,2016
3. Association between Bone marrow lesions&synovitis and symptoms in symptomatic knee osteoarthritis;Osteoarthr. Cartil.,2019
4. Synovial inflammation in osteoarthritis progression;Nat. Rev. Rheumatol.,2022
5. Phenotypic Characterization of Inflammatory Cells from Osteoarthritic Synovium and Synovial Fluids;Clin. Immunol.,2002
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献